NEW YORK (GenomeWeb News) - Nanogen has submitted an influenza diagnostic to the US Centers for Disease Control and Prevention for evaluation for further development, the company said today.
Nanogen said this submission fulfills a second-phase milestone requirement on a contract CDC awarded to Nanogen and its business partner, the San Francisco-based HX Diagnostics.
The company said it will continue to develop the point-of-care influenza diagnostic and will undertake clinical trials pending approval and funding from the CDC.
Around 36,000 people in the US die each year from influenza infections, the company said.
The CDC is concerned about the possibility of a deadly influenza subtype arising and causing a pandemic and is funding development of tests that can act as “sentinels” for potential outbreaks, Nanogen said.